Related Experiment Video
Updated: Aug 10, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
Published on: February 24, 2014
Specific gene mutations in L5178Y cells in culture
Abstract:
The predominant test system uses a near-diploid L5178Y mouse lymphoma cell line and is based on the quantitation of forward mutations occurring at the heterozygous thymidine kinase (TK) locus (TK+/- leads to TK-/-). (Other markers, such as ouabain- or methothrexate-resistance and alanine independence, in other L5178Y mouse lymphoma cells were also examined, but our criteria for the acceptability of data or the paucity of data considerably reduced the value of these mutagenesis test systems to this study.) The biochemical basis for the L5178Y/TK+/- assay depends on the ability of TK-competent cells to phosphorylate 5-bromo-2'-deoxyuridine or trifluorothymidine. The phosphorylated product or its metabolites kill these cells, thus, medium containing 5-bromo-2'-deoxyuridine or trifluorothymidine is capable of selecting for cells that are lacking the TK enzyme (TK-/-). TK-/- cells eventually give rise to a bimodal distribution of colony sizes. The relative proportion of small and large colonies appears to be characteristic of the mutagen, its dose, and the length of the expression period. A total of 108 references were reviewed and 48 chemical agents were evaluated. Of these, in vivo carcinogenicity data existed for 44 and covered a wide variety of chemical classes (43 compounds) and a complex mixture. In this system, 39 agents were positive, 1 was negative, and 4 yielded inconclusive results. The 44 test substances evaluated were insufficient to single out agents or agent classes for which the assay was particularly well suited; however, with the exception of thymidine analogs, the system seems to be versatile. The correlation of the TK locus assay results with the carcinogenicity data revealed that 2 agents were definite false positives (sodium azide and methotrexate) and 1 agent was a definite false negative (1,1-dimethylhydrazine). Further evaluation suggested that 4-acetylaminofluorene and diphenylnitrosamine were questionable false positives, while benzo[e]pyrene was a questionable false negative. (The term questionable was used to imply uncertainties concerning the mutagenicity and/or carcinogenicity data). Thus, the assay is of value in the battery approach to mutagenicity/carcinogenicity screening.
Insights
The L5178Y mouse lymphoma cell assay effectively screens for mutagenicity, identifying 39 of 48 agents. While generally versatile, it showed some false positives and negatives when compared to carcinogenicity data.
Area of Science:
- Biochemistry and Molecular Toxicology
- Genotoxicity Testing
- Mammalian Cell Assays
Background:
- The L5178Y mouse lymphoma cell line is a key system for assessing mutagenicity.
- The thymidine kinase (TK) locus assay (TK+/- to TK-/-) quantifies forward mutations.
- TK-competent cells phosphorylate nucleoside analogs, enabling selection of TK-deficient mutants.
Purpose of the Study:
- To evaluate the utility of the L5178Y/TK+/- assay in mutagenicity screening.
- To assess the performance of the assay against existing in vivo carcinogenicity data.
- To determine the assay's suitability as part of a broader mutagenicity/carcinogenicity testing battery.
Main Methods:
- Utilized a near-diploid L5178Y mouse lymphoma cell line for TK locus mutation analysis.
- Evaluated 48 chemical agents, assessing forward mutations at the heterozygous TK locus.
- Compared assay results with in vivo carcinogenicity data for 44 of the tested agents.
Main Results:
- The assay identified 39 out of 48 agents as positive mutagens, with 1 negative and 4 inconclusive results.
- Correlation with carcinogenicity data revealed 2 definite false positives (sodium azide, methotrexate) and 1 definite false negative (1,1-dimethylhydrazine).
- The assay demonstrated versatility across various chemical classes, excluding thymidine analogs.
Conclusions:
- The L5178Y/TK+/- assay is a valuable tool for mutagenicity screening.
- The assay shows promise for inclusion in a battery approach for carcinogenicity assessment.
- Further investigation is needed to refine understanding of discrepancies with carcinogenicity data.

